Am J Stem Cell 2012;1(3):253-263

Review Article
Applications of skeletal muscle progenitor cells for neuromuscular diseases

Tohru Hosoyama, Jonathan Van Dyke, Masatoshi Suzuki

Department of Comparative Biosciences, The Stem Cell and Regenerative Medicine Center of Wisconsin-Madison, University of
Wisconsin-Madison, Madison, WI, USA

Received October 19, 2012; Accepted November 5, 2012; Epub November 30, 2012; Published December 10, 2012

Abstract: Neuromuscular diseases affect skeletal muscle and/or nervous control resulting in direct disruption of skeletal muscle and
muscle pathology, or nervous system disruption which indirectly disrupts muscle function. Stem cell-based therapy is well-recognized as
a promising approach for several types of diseases including those affecting the neuromuscular system. To design a successful
therapeutic strategy, it is important to choose the most appropriate stem cell type. Skeletal muscle progenitor cells (SMPCs), also called
myogenic progenitors, can contribute to muscle regeneration, differentiate into skeletal muscles, and are valuable cells for therapeutic
application. Different types of stem/progenitor cells, including satellite cells, side population cells, muscle derived stem cells,
mesenchymal stem cells, myogenic pericytes, and mesoangioblasts, have been identified as possible cell resources of SMPCs.
Furthermore, recent advances in stem cell biology allow us to use embryonic stem cells and induced pluripotent stem cells for SMPC
derivation. When skeletal muscle is chosen as a target of cell transplantation, the possible criteria for choosing the “best”
progenitor/stem cell include preparation strategies, efficiency of intramuscular integration, method of cellular delivery, and functional
improvement of the muscle after cell transplantation. Here, we discuss recent findings on various types of SMPCs and their promise for
future clinical translation in neuromuscular diseases. (AJSC1210002).

Keywords: Neuromuscular diseases, cell-based therapy, skeletal muscle progenitor cells (SMPCs), pluripotent stem cells (PSCs),
transplantation


Address all correspondence to:
Dr. Masatoshi Suzuki
Department of Comparative Biosciences
University of Wisconsin-Madison
2015 Linden Drive, Madison, WI 53706, USA.
Tel: (608) 2624264; Fax: (608) 8903667
E-mail: msuzui@svm.vetmed.wisc.edu
AJSC Copyright © 2011-present. All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA